指南与共识MDS 与骨髓增殖性肿瘤

减少骨髓增生异常综合征患者临床试验入组障碍:icMDS立场声明

Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement.
指南 / 共识 · Blood · 2025-01-01

国际骨髓增生异常综合征联盟(icMDS)针对MDS临床试验中过严的入排标准发布立场声明。该声明基于对2000年1月1日至2023年9月1日期间在ClinicalTrials.gov注册的191项治疗性MDS试验的分析,发现各期试验的分类入排标准高度相似,且仅13%的试验与药物安全性信号一致。声明列出了应避免的限制性入排标准,旨在消除入组障碍。

要点

  • 临床试验入排标准应反映研究阶段和药物风险,3期试验应比早期试验限制更少。
  • 对191项MDS试验的分析显示,各期试验的分类入排标准高度相似。
  • 仅13%的试验入排标准与药物安全性信号一致,提示标准常具有随意性。

核心结论

  • icMDS发布立场声明,列出MDS临床试验中应避免的限制性入排标准,以消除入组障碍。

研究设计与样本

  • icMDS(国际骨髓增生异常综合征联盟)基于对2000年1月1日至2023年9月1日ClinicalTrials.gov注册的191项治疗性MDS试验的入排标准分析,发布立场声明。

主要发现

  • 各期试验的分类纳入和排除标准在表述上高度相似。
  • 仅13%的试验入排标准与药物安全性信号一致。

关键数值与推荐

  • 临床试验入排标准应反映研究阶段和所研究药物的风险。
  • 3期试验应比早期试验限制更少,以尽可能接近真实世界人群。
  • 声明列出了MDS临床试验中应避免的限制性入排标准。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Excessively restrictive inclusion and exclusion criteria in clinical trials are one of many barriers to clinical trial enrollment for patients with myelodysplastic syndromes/neoplasms (MDSs). Many organizations are developing efforts to increase clinical trial eligibility; yet, several recent publications focused on patients with MDS suggest that many patients with this disease may be excluded from clinical trials unnecessarily. Clinical trial eligibility should reflect the phase of the study and risks of the agent being studied. Phase 3 trials should be less restrictive than early-phase trials to represent the real-world population as closely as possible. We hypothesize that many clinical trials, particularly phase 3 trials, have unnecessarily restrictive eligibility criteria. This study aims to evaluate the most common eligibility criteria according to phase of trial and to determine whether criteria correspond with drug safety signals. We identified MDS clinical trials registered on ClinicalTrials.gov from 1 January 2000 to 1 September 2023 and analyzed the eligibility criteria of 191 therapeutic MDS trials. We found that categorical inclusion and exclusion criteria are remarkably similar in representation across trial phases. Additionally, only 13% of trials are concordant with drug safety signals, suggesting that the eligibility criteria are often arbitrary. On behalf of the icMDS (International Consortium for Myelodysplastic Syndromes), an association of international MDS experts, we provide a position statement on restrictive eligibility criteria for MDS clinical trials that should be avoided with the aim of removing barriers to clinical trial enrollment.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Borate U, Pugh K, Waller A, et al. Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement. Blood. 2025. PMID: 40146152. doi:10.1182/blood.2023023717

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。